Generex Biotechnology (GNBT) Inventory Turnover Ratio, from third quarter 2021 to third quarter 2020, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 
Generex Biotechnology Corp  (GNBT)
 

Generex Biotechnology Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Generex Biotechnology Corp inventory turnover ratio, the Generex Biotechnology Corp's ability to sell and replace its inventory in the third quarter 2021, sequentially increased to 0.62 in the third quarter 2021, yet the ratio remained below the average, as GNBT's market remain challenging.Average inventory processing period, for the Generex Biotechnology in Apr 30 2021 quarter, has decreased to 589 days, compare to 664 days, in the Jan 31 2021 quarter.

Within Healthcare sector 378 other companies have achieved higher inventory turnover ratio. While Inventory turnover ratio total ranking has improved so far during the III Quarter 2021, to 1952, from total ranking in the second quarter 2021 at 1955.

GNBT Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Generex Biotechnology Corp Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GNBT Inventory Turnover Ratio (Apr 30 2021)
III. Quarter		 (Jan 31 2021)
II. Quarter		 (Oct 31 2020)
I. Quarter		 (Jul 31 2020)
IV. Quarter		 (Apr 30 2020)
III. Quarter
Y / Y Inventory Growth -74.52 % -28.24 % 97.96 % 196.88 % -17.15 %
Y / Y Cost of Sales Growth -43.25 % -36.63 % -82.54 % - -44.45 %
Inventory Turnover Ratio (TTM) 0.62 0.55 0.58 0.81 0.68
GNBT's Total Ranking # 1952 # 1955 # 1952 # 1384 # 1179
Average inventory processing period 588 667 628 453 535
Seq. Inventory Growth -62.43 % -14.02 % -3.18 % -18.52 % 5.79 %
Seq. Cost of Sales Growth -37.14 % 349.94 % -85.8 % 41.27 % -29.8 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 130
Healthcare Sector # 379
Overall Market # 1952

Inventory Turnover Ratio Statistics
High Average Low
4.1 1.82 0.55
(Jul 31 2019)   (Jan 31 2021)



GNBT Company Profile >> Back to GNBT Efficiency Comparisons >> Compare GNBT Inventory Turnover Ratio to its Competitors

Financial Statements
Generex Biotechnology's Inventories $ 0 Millions Visit GNBT's Balance sheet
Generex Biotechnology's Cost of Revenues TTM $ 0 Millions Visit GNBT's Income Statement
What are GNBT's Sales? Visit GNBT's Sales by Segment

Other Inventory Turnover Ratios
Generex Biotechnology's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
GNBT's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for GNBT's Competitors
Inventory Turnover Ratio for GNBT's Suppliers
Inventory Turnover Ratio for GNBT's Customers

You may also want to know
GNBT's Sales Growth Rates GNBT's Pe Price to earnings ratio GNBT's Receivables Turnover Ratio GNBT's Stock Quote
GNBT's Net Income Growth Rates GNBT's Ps Price to Sales ratio GNBT's Sales per Employee GNBT's Asset Turnover Ratio
GNBT's Net Margin GNBT's Pb Price to Book ratio GNBT's Financial Strength Ratios GNBT's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Apr 30 2021, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Apr 30 2021 Inventories at quarter ending Apr 30 2021
Mallinckrodt Plc  4.25 $ 1,469.600  Millions$ 346  Millions
Glaukos Corp  4.21 $ 75.823  Millions$ 18  Millions
Aquestive Therapeutics Inc   4.13 $ 12.062  Millions$ 3  Millions
Akebia Therapeutics Inc   4.06 $ 302.801  Millions$ 75  Millions
Immucell Corporation  4.05 $ 8.310  Millions$ 2  Millions
Global Cord Blood Corp  4.04 $ 27.313  Millions$ 7  Millions
Envista Holdings Corporation  4.04 $ 1,048.300  Millions$ 259  Millions
3m Company  4.04 $ 17,021.000  Millions$ 4,212  Millions
Novocure Limited  4.01 $ 108.390  Millions$ 27  Millions
Orthofix Medical Inc   4.00 $ 104.212  Millions$ 26  Millions
Integrated Biopharma Inc  3.97 $ 51.378  Millions$ 13  Millions
Myomo Inc   3.95 $ 2.905  Millions$ 1  Millions
Logicmark Inc  3.94 $ 3.182  Millions$ 1  Millions
Therapeutic Solutions International Inc   3.93 $ 0.020  Millions$ 0  Millions
Tandem Diabetes Care Inc   3.92 $ 258.395  Millions$ 66  Millions
Endo International Plc  3.88 $ 1,359.005  Millions$ 350  Millions
China Health Industries Holdings Inc   3.84 $ 3.433  Millions$ 1  Millions
Sonoma Pharmaceuticals Inc   3.83 $ 12.070  Millions$ 3  Millions
Teva Pharmaceutical Industries Limited  3.76 $ 8,743.000  Millions$ 2,324  Millions
Alpha Pro Tech Ltd   3.73 $ 56.600  Millions$ 15  Millions
Baxter International Inc   3.70 $ 7,248.000  Millions$ 1,957  Millions
Vyne Therapeutics Inc   3.65 $ 25.470  Millions$ 7  Millions
Agilent Technologies inc   3.63 $ 2,705.000  Millions$ 744  Millions
Gilead Sciences Inc   3.60 $ 4,964.000  Millions$ 1,381  Millions
Harrow Inc   3.59 $ 14.607  Millions$ 4  Millions
Mimedx Group Inc   3.58 $ 38.946  Millions$ 11  Millions
Escalon Medical Corp   3.58 $ 5.841  Millions$ 2  Millions
Evolus Inc   3.56 $ 18.988  Millions$ 5  Millions
Gw Pharmaceuticals Plc  3.56 $ 38.569  Millions$ 11  Millions
Sintx Technologies Inc   3.54 $ 0.370  Millions$ 0  Millions

Date modified: 2026-09-08T15:10:18+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.